

**VERIFIED STATEMENT CLAIMING SMALL ENTITY STATUS
(37 CFR 1.9(e)(1) & 1.27(d)) — NON-PROFIT ORGANIZATION**

In re United States Patent Application:

Serial No.	Inventors	Filing Date	Title
Not Available	Gallo et al.	December 24, 1998	Peptides from β -hCG, Fractions of hCG Sources and Therapeutic Methods Employing Such Peptides and/or Fractions

I hereby declare that I am an official of the non-profit organization empowered to act on behalf of the concern identified below:

**UNIVERSITY OF MARYLAND
BIOTECHNOLOGY INSTITUTE
4321 Hartwick Rd., Suite 500
College Park, MD 20740**

I hereby declare that the above identified entity qualifies as a non-profit organization as defined in 37 CFR 1.9(e)(1), for purposes of paying reduced fees to the United States Patent and Trademark Office, in that the entity is a university or other institute of higher education located in United States.


I hereby declare that rights under contract or law have been conveyed to and remain with the non-profit organization identified above with regard to the invention described in the above identified United States Patent Applications.

The following entity owns non-U.S. rights in the invention: **University of Maryland Biotechnology Institute.** No other rights are outstanding.


I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at any time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate (37 CFR 1.28(b)).

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

SIGNATURE:



DATE:



NAME:

Claudia Haywood

TITLE:

Assistant Vice-president
Research Administration and Technology Development

ADDRESS:

4321 Hartwick Rd., Suite 500
College Park, MD 20740

09677152-100200

DECLARATION AND POWER OF ATTORNEY FOR PATENT APPLICATION

As the below-named inventor, I hereby declare that my residence, post office address and citizenship are as stated below next to my name.

I believe I am the original first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled, **"PEPTIDES FROM β -hCG, FRACTIONS OF hCG SOURCES AND THERAPEUTIC METHODS EMPLOYING SUCH PEPTIDES AND/OR FRACTIONS"**, the specification of which was filed in the U.S. Patent and Trademark Office on December 24, 1998.

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, §1.56(a).

I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed.

Number	Title	Filing Date
PCT/US97/11210	Treatment and Prevention of Cancer by Administration of Derivatives of Human Chorionic Gonadotropin	June 24, 1998
PCT/US97/11209	Methods of Promoting Hematopoiesis using Derivatives of Human Chorionic Gonadotropin	June 24, 1998
PCT/US97/11448	Treatment and Prevention of Wasting syndrome Based on Administration of Human Chorionic Gonadotropin	June 24, 1998
PCT/US97/11202	Treatment and Prevention of HIV Infection by Administration of Derivatives of Human Chorionic Gonadotropin	June 24, 1998

I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

STEVEN J. HULTQUIST, REG. NO. 28,021
WILLIAM A. BARRETT, REG. NO. 42,296

All correspondence in connection with this application should be sent to:

Steven J. Hultquist
Intellectual Property/Technology Law
P. O. Box 14329
Research Triangle Park, NC 27709
Telephone: (919) 419-9350

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements are made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full Name of first inventor: **Robert C. Gallo**
Inventor's Signature *R. Gallo* Date 2/11/99
Residence: 8513 Thornden Terrace, Bethesda, MD 02817
Citizenship: U.S.A.
Post Office Address: 8513 Thornden Terrace, Bethesda, MD 02817

Full Name of second inventor: **Joseph Bryant**
Inventor's Signature *J. Bryant* Date 2-11-99
Residence: 732 Ivy League Lane, Rockville, MD 20850
Citizenship: U.S.A.
Post Office Address: 732 Ivy League Lane, Rockville, MD 20850

Full Name of third inventor: **Yanto Lunardi-Iskandar**
Inventor's Signature *Y. Lunardi-Iskandar* Date 02/11/99
Residence: 226 Lee Street, Gaithersburg, MD 20877
Citizenship: FR
Post Office Address: 226 Lee Street, Gaithersburg, MD 20877